Lifastuzumab vedotin
Appearance
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | phosphate-sodium cotransporter |
Clinical data | |
Other names | DNIB0600A |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C6504H10028N1744O2018S46 |
Molar mass | 151.7 kg/mol g·mol−1 |
Lifastuzumab vedotin (DNIB0600A) (INN[1]) is a monoclonal antibody designed for the treatment of cancer.[2]
This drug was developed by Genentech/Roche.